Zymeworks will pay $17.00/share (~$929M) for Theravance, prioritizing Yupelri-linked profitability and planned post-close ...
It was a jarring experience that stemmed from a startlingly common misconception: that adults don't get T1D; however, she is ...
A July 17 response deadline requires documentation of trial-site governance in China, emphasizing due diligence, data protection controls, and monitoring of compliance at Xinjiang and PLA-affiliated ...
Troutman Pepper Locke senior associate Ryan Last explains when markets will start to significantly react to the upcoming pharma tariffs. In April of this year, President Trump announced plans to ...
In today's Pharmaceutical Executive Daily, AbbVie announces a $10.9 billion agreement to acquire Apogee Therapeutics, adding ...
In today's Pharmaceutical Executive Daily, the FDA approves Gilead's Trodelvy for the first-line treatment of metastatic ...
FDA selected seven participants from 80+ requests using a scoring rubric emphasizing supply need, facility development stage, time-to-market, and manufacturing innovation. Amneal will make sterile ...
Resilient field models emphasize continuous territory coverage via agile deployment, blending scalable virtual reach with ...
FDA’s PreCheck Pilot Program aims to de-risk and accelerate domestic capacity buildouts via earlier regulatory interaction, aligning manufacturing policy with supply-chain resilience priorities.
They want to make sure we've got more control over that supply chain, so DARPA and the federal government are really ...
In today's Pharmaceutical Executive Daily, a pharma M&A roundup covers Ipsen's up to $1.75 billion acquisition of Kartos Therapeutics and Zymeworks' $929 million acquisition of Theravance Biopharma, ...
For pharmaceutical executives, the transition from just extending to fully optimizing life is a defining commercial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results